Loading
Signet Therapeutics is a Shenzhen company that uses lab-grown tumour models and AI to find new targeted cancer drugs. Its lead drug, SIGX1094, is aimed at diffuse gastric cancer and is in an early trial in Beijing.
Signet Therapeutics (Shenzhen) Co., Ltd. started on the Harvard University campus and moved to Shenzhen at the end of 2020, according to the company; its founder and chief executive Haisheng Zhang was a postdoctoral fellow at Dana-Farber Cancer Institute, and Adam Bass is a co-founder. It combines patient-derived organoid disease models with AI to discover small-molecule targeted drugs. Its lead programme SIGX1094, which the company describes as the first targeted drug for diffuse gastric cancer, has US FDA and Chinese NMPA investigational new drug clearances and FDA orphan drug and Fast Track designations, and is in a phase 1 trial at Peking University Cancer Hospital; SIGX2649, a pan-TEAD inhibitor acting on the Hippo pathway, received FDA IND clearance in May 2026. The company states it has raised nearly CNY 300 million in financing and project grants, including a CNY 80 million Series A in January 2026 from investors including XtalPi and Songhe Capital. Its first registered cancer trial, NCT06739291, a phase 1 study of SIGX1094R in advanced solid tumours in Beijing, was posted on ClinicalTrials.gov in December 2024.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series A · CNY 80 million, jointly from XtalPi, Songhe Capital and three other investors, per the company timeline | 2026 | undisclosed | signettx.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares AI-driven drug & target discovery, Patient-derived organoids.
Shares AI-driven drug & target discovery, Gastric & gastro-oesophageal junction cancer.
Shares AI-driven drug & target discovery, Patient-derived organoids.
Shares AI-driven drug & target discovery, Patient-derived organoids.
Shares AI-driven drug & target discovery, Patient-derived organoids.
Shares AI-driven drug & target discovery, Patient-derived organoids.
Shares Patient-derived organoids, Gastric & gastro-oesophageal junction cancer.
Shares AI-driven drug & target discovery, Gastric & gastro-oesophageal junction cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/